Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

The Seattle Times

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Thursday, February 28, 2008 at 12:00 AM

E-mail article     Print view

$19 million for biotech startup PhaseRx

Venture capitalists have agreed to nurture PhaseRx, a nascent Seattle biotech, with funding of up to $19 million to pursue a pioneering technique that could help turn off harmful genes.

Seattle Times business reporter

Venture capitalists have agreed to nurture PhaseRx, a nascent Seattle biotech, with funding of up to $19 million to pursue a pioneering technique that could help turn off harmful genes.

The financing, led by ARCH Venture Partners, 5AM Ventures and Versant Ventures, starts with a $4 million upfront investment.

The remainder will be available upon hitting some research milestones, such as putting the theory behind its technology into practice, and reaching certain business objectives the firm declined to disclose.

The rest of the investment could come in the next 24 months, said founder Bob Overell.

PhaseRx seeks to develop a way to deliver therapies based on siRNA, or small interfering RNA, a technique that allows genes linked to maladies to be switched off.

That research field is one of the hottest in the biotechnology sector, said David Miller, an analyst with Biotech Stock Research. In late 2006, pharma giant Merck paid $1.1 billion for Sirna Therapeutics, triggering a "land rush" on small private companies working in the field, Miller said. Interest in this new field is "huge," he said.

Another local biotech, Nastech Pharmaceutical, aims to spin off its RNA interference research program into a separate firm. One of its former executives, Paul Johnson, is the founding chief scientific officer of PhaseRx.

PhaseRx was put together by Overell, a former Frazier Healthcare Ventures partner who now heads Foundation BioVentures in Seattle. Other founders include University of Washington researchers Patrick Stayton and Allan Hoffman, and Oliver Press of the Fred Hutchinson Cancer Research Center.

Despite the RNA interference hype, the technology has a long way to go, said Miller. "Nobody has figured out how to deliver an RNA-based drug in humans yet."

But PhaseRx founders are optimistic. They said in a statement that the polymer technology the company licensed from Stayton and Hoffman's laboratories at the UW "enables the effective delivery" of interfering RNA and other therapies into living animals.

This is the second local budding biotech recently funded by ARCH Ventures. The firm in November led a $12 million financing round for Fate Therapeutics, which seeks to develop stem-cell based therapies.

ARCH managing director Steven Gillis, a co-founder of Immunex and Corixa, will become PhaseRx's chairman.

Ángel González: 206-515-5644

Copyright © 2008 The Seattle Times Company

More Business & Technology headlines...

E-mail article Print view      Share:    Digg     Newsvine

advertising

Chase shrugs off loss of CD investors

Sunday Buzz: Expedia, Intelius, Classmates slapped by Senate report

Denny Triangle gains skyline, but tenants slow to come

UPDATE - 08:56 PM
Senate Democrats at odds over health care bill

Your Funds: Money for nothing: Some investors pay for advice they never get

Advertising

Video

Raw Video | Real Salt Lake receives the MLS Cup trophy
Real Salt Lake is handed the 2009 MLS Cup trophy at Qwest Field, November 22, 2009.

Raw Video | Real Salt Lake fans celebrate
Raw Video | MLS Cup Opening Ceremony
Real Salt Lake fans enter Qwest Field
LA Galaxy's David Beckham
Real Salt Lake's Kyle Beckerman
MLS trophy arrives in Seattle
Chittenden Locks Inspection
Full interview with New Moon actors
Interview with New Moon actors

Marketplace

nwautos

2009's most fuel-efficient sedansnew
Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment

Open Houses

Find this weekend's open house listings.
Or search by location:

 
Most read
Most commented
Most e-mailed
 
 
Advertising